Showing 3711-3720 of 4164 results for "".
- Iantrek Announces Positive Efficacy and Safety Profile of its Bio-Interventional Technologyhttps://modernod.com/news/iantrek-announces-positive-efficacy-and-safety-profile-of-its-bio-interventional-technology-to-enhance-uveoscleral-outflow-in-glaucoma-patients/2482707/Iantrek Corporation today announced positive results from its 2-year prospective clinical study evaluating its bio-reinforced cyclodialysis technology. The study, published in Ophthalmology Science, affirms the safety and efficacy of Iantrek’s bio-interventional technology to enhance&n
- Experimental Stem Cell Treatment Shows Success in Restoring Corneashttps://modernod.com/news/experimental-stem-cell-treatment-shows-success-in-restoring-corneas/2482700/A clinical trial testing an stem cell treatment for blinding cornea injuries has shown promising results. The expanded phase 1/2 trial, published in Nature Communications[1] found the treatment to be feasible and safe for 14 pa
- Opthea Publishes Phase 2b Trial Data for Wet AMDhttps://modernod.com/news/opthea-publishes-promising-phase-2b-trial-data-for-wet-amd/2482685/Opthea announced new data from the phase 2b clinical trial using sozinibercept to treat wet age-related macular degeneration (AMD). The results were published in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. Opthea’s complete phase 3 wet AMD
- Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolaminehttps://modernod.com/news/opus-genetics-announces-fda-fast-track-and-enrollment-updates-for-phentolamine-ophthalmic-solution/2482681/Opus Genetics announced completion of enrollment in the VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia. Opus also announced that enrollment in the LYNX-2 pivotal phase 3 trial, evaluating phentolamine for the treat
- Opus Genetics Doses First Pediatric Patient in Phase 1/2 Trial for OPGx-LCA5 Gene Therapyhttps://modernod.com/news/opus-genetics-doses-first-pediatric-patient-in-phase-12-trial-for-opgx-lca5-gene-therapy/2482675/Opus Genetics announced the first pediatric patient has been dosed in its ongoing phase 1/2 clinical trial evaluating OPGx-LCA5, its investigational gene therapy for Leber congenital amaurosis (LCA). Initial data from the pediatric cohort is expected to be shared by Q3
- TECLens Secures $9.3 Million Series A Funding to Advance Its Noninvasive Refractive Technologyhttps://modernod.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/TECLens announced it raised $9.3 million in a Series A round to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. The funding round was co-led by Johnson &
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Studyhttps://modernod.com/news/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study/2482654/4D Molecular Therapeutics (4DMT) announced positive initial interim 52-week data from the phase 2b population extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (AMD) patient population. Additional data were provided on the durabili
- Qlaris Bio Announces Positive Topline Data From Two Phase 2 Trials of QLS-111 for Glaucomahttps://modernod.com/news/qlaris-bio-announces-positive-topline-data-from-two-phase-2-trials-of-qls-111-for-glaucoma/2482647/Qlaris Bio announced positive topline results from two US phase 2 clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). The trials (Osprey and Apteryx) successfully met all primary and secondary endpoints. Qlaris Bi
- MERIT Acquires OSOD to Expand Ophthalmic Drug Development Serviceshttps://modernod.com/news/merit-acquires-osod-to-expand-ophthalmic-drug-development-services/2482629/MERIT announced its has acquired OSOD, which assists with ophthalmic preclinical drug development. The acquisition enhances MERIT’s capabilities, enabling a transition from preclinical to clinical phases of drug development. Accordin
- Inflammasome Therapeutics Announces Positive Topline Data from K8 Implant Trial for GAhttps://modernod.com/news/inflammasome-therapeutics-announces-positive-topline-data-from-k8-implant-trial-for-geographic-atrophy/2482621/Inflammasome Therapeutics reported 3-month results from a clinical trial of its K8 implant in patients with geographic atrophy (GA). The study, conducted at the University of Kentucky (NCT06164587), demonstrated significant efficacy and safety following a single inject